Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

iRhythm Technologies, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK , NOV. 17, 2025 /PRNEWSWIRE/ -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF IRHYTHM TECHNOLOGIES, INC. (NASDAQ: IRTC) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. ACCORDING TO A FEDERAL SECURITIES LAWSUIT, INSIDERS AT IRHYTHM CAUSED THE COMPANY TO MISREPRESENT OR FAIL TO DISCLOSE THAT THE ZIO AT MONITOR WAS A REAL-TIME MONITOR INTENDED FOR HIGH-RISK PATIENTS.

KUEHN LAW ENCOURAGES INVESTORS OF IRHYTHM TECHNOLOGIES, INC. TO CONTACT LAW FIRM

NEW YORK, NEW YORK--(NEWSFILE CORP. - NOVEMBER 12, 2025) - KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF IRHYTHM TECHNOLOGIES, INC. (NASDAQ: IRTC) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. ACCORDING TO A FEDERAL SECURITIES LAWSUIT, INSIDERS AT IRHYTHM CAUSED THE COMPANY TO MISREPRESENT OR FAIL TO DISCLOSE THAT THE ZIO AT MONITOR WAS A REAL-TIME MONITOR INTENDED FOR HIGH-RISK PATIENTS.

NEW HEART RHYTHM JOURNAL PUBLICATION AND AHA 2025 DATA REINFORCE ZIO LTCM CLINICAL VALUE AND REAL-WORLD EVIDENCE SUPPORTING PROACTIVE CARDIAC MONITORING.

IRHYTHM TECHNOLOGIES ANNOUNCES PUBLICATION OF LARGE-SCALE STUDYIN HEART RHYTHM AND NEW DATA PRESENTED AT AHA SCIENTIFIC SESSIONS 2025

SAN FRANCISCO, NOV. 04, 2025 (GLOBE NEWSWIRE) -- IRHYTHM TECHNOLOGIES, INC. (NASDAQ:IRTC), A LEADING DIGITAL HEALTH CARE COMPANY FOCUSED ON CREATING TRUSTED SOLUTIONS THAT DETECT, PREVENT, AND PREDICT DISEASE, TODAY ANNOUNCED THAT ITS MANAGEMENT TEAM IS SCHEDULED TO PRESENT AT THE FOLLOWING INVESTOR CONFERENCES.

IRHYTHM TECHNOLOGIES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

SAN FRANCISCO, OCT. 30, 2025 (GLOBE NEWSWIRE) -- IRHYTHM TECHNOLOGIES, INC. (NASDAQ: IRTC), A LEADING DIGITAL HEALTH CARE COMPANY FOCUSED ON CREATING TRUSTED SOLUTIONS THAT DETECT, PREDICT, AND PREVENT DISEASE, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER30, 2025.

IRHYTHM TECHNOLOGIES ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS

NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER CERTAIN OFFICERS AND DIRECTORS OF IRHYTHM TECHNOLOGIES, INC. (NASDAQ: IRTC) BREACHED THEIR FIDUCIARY DUTIES TO SHAREHOLDERS. IF YOU CURRENTLY OWN IRHYTHM STOCK AND ACQUIRED SHARES ON OR BEFORE NOVEMBER 5, 2021, YOU MAY BE ABLE TO SEEK CORPORATE GOVERNANCE REFORMS, THE RETURN OF FUNDS BACK TO THE COMPANY, A COURT-APPROVED FINANCIAL INCENTIVE AWARD, OR OTHER RELIEF AND BENEFITS. PLEASE CLICK HERE TO.

HALPER SADEH LLC ENCOURAGES IRHYTHM TECHNOLOGIES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

SAN FRANCISCO, OCT. 16, 2025 (GLOBE NEWSWIRE) -- IRHYTHM TECHNOLOGIES, INC. (NASDAQ:IRTC), A LEADING DIGITAL HEALTH CARE COMPANY FOCUSED ON CREATING TRUSTED SOLUTIONS THAT DETECT, PREVENT, AND PREDICT DISEASE, TODAY ANNOUNCED THAT IT WILL RELEASE FINANCIAL RESULTS FOR THE THIRD QUARTER 2025 AFTER THE CLOSE OF TRADING ON THURSDAY, OCTOBER 30, 2025. THE COMPANY'S MANAGEMENT TEAM WILL HOST A CORRESPONDING CONFERENCE CALL BEGINNING AT 1:30 P.M.

IRHYTHM TECHNOLOGIES TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON OCTOBER 30, 2025

SAN FRANCISCO, AUG. 20, 2025 (GLOBE NEWSWIRE) -- IRHYTHM TECHNOLOGIES, INC. (NASDAQ:IRTC), A LEADING DIGITAL HEALTH CARE COMPANY FOCUSED ON CREATING TRUSTED SOLUTIONS THAT DETECT, PREVENT, AND PREDICT DISEASE, TODAY ANNOUNCED THAT ITS MANAGEMENT TEAM IS SCHEDULED TO PRESENT AT THE FOLLOWING INVESTOR CONFERENCES.

SAN FRANCISCO, AUG. 18, 2025 (GLOBE NEWSWIRE) -- IRHYTHM TECHNOLOGIES, INC . (NASDAQ:IRTC) ANNOUNCED THE PUBLICATION OF THE REAL-WORLD EVIDENCE STUDY: ASSESSMENT OF VARIATION IN AMBULATORY CARDIAC MONITORING: REAL-WORLD EVIDENCE OF COMMERCIALLY INSURED BENEFICIARIES (AVALON) IN THE AMERICAN JOURNAL OF MANAGED CARE REINFORCING THE CLINICAL SUPERIORITY OF THE ZIO LONG-TERM CONTINUOUS MONITORING (LTCM) SERVICE.

AVALON REAL-WORLD EVIDENCE BUILDS ON CAMELOT STUDYREINFORCING IRHYTHM'S ZIO LTCM CLINICAL SUPERIORITY

SAN FRANCISCO, JULY 31, 2025 (GLOBE NEWSWIRE) -- IRHYTHM TECHNOLOGIES, INC.(NASDAQ: IRTC), A LEADING DIGITAL HEALTH CARE COMPANY FOCUSED ON CREATING TRUSTED SOLUTIONS THAT DETECT, PREDICT, AND PREVENT DISEASE, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE30, 2025. SECOND QUARTER 2025 FINANCIAL HIGHLIGHTS REVENUE OF $186.7 MILLION, A 26.1% INCREASE COMPARED TO SECOND QUARTER 2024 GROSS MARGIN OF 71.2%, A 130-BASIS POINT INCREASE COMPARED TO SECOND QUARTER 2024 UNRESTRICTED CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $545.5 MILLION AS OF JUNE30, 2025 INCREASED FISCAL YEAR 2025 GUIDANCE FOR REVENUE AND ADJUSTED EBITDA RECENT OPERATIONAL HIGHLIGHTS SECOND QUARTER 2025 RECORD QUARTERLY REVENUE DRIVEN BY CONTINUED MOMENTUM IN OUR CORE LONG-TERM CONTINUOUS MONITORING BUSINESS, SUSTAINED DEMAND FOR ZIO AT, PROGRESS WITHIN INNOVATIVE VALUE-BASED CARE ACCOUNTS, AND CONTRIBUTION FROM INTERNATIONAL MARKETS EXECUTED STRATEGIC PARTNERSHIP WITH LUCEM HEALTH, A LEADER IN AI-DRIVEN EARLY DISEASE DETECTION, TO ACCELERATE EARLY IDENTIFICATION OF UNDIAGNOSED ARRHYTHMIAS IN PATIENT POPULATIONS WITH COMORBID CONDITIONS, A BOLD STEP TOWARD PREDICTIVE, PREVENTIVE, AND PRECISE CARE THAT IS POWERED BY AI, INFORMED BY DATA, AND DESIGNED FOR SCALE1 RESULTS FROM TWO LARGE-SCALE REAL-WORLD STUDIES PRESENTED AT THE AMERICAN DIABETES ASSOCIATION'S 85TH SCIENTIFIC SESSIONS (ADA 2025) DEMONSTRATED THAT CARDIAC ARRHYTHMIAS PRESENT FREQUENT, EARLY, AND OFTEN PRECEDING MAJOR CARDIOVASCULAR EVENTS (MACE), HIGHLIGHTING A CRITICAL OPPORTUNITY TO ENHANCE EARLY DETECTION STRATEGIES IN AT-RISK CARDIOMETABOLIC POPULATIONS "THE SECOND QUARTER OF 2025 WAS ANOTHER RECORD QUARTER FOR IRHYTHM, WITH GROWTH OF MORE THAN 26%, SHOWCASING THE STRENGTH OF OUR DIVERSIFIED GROWTH STRATEGY," SAID QUENTIN BLACKFORD, PRESIDENT AND CHIEF EXECUTIVE OFFICER OF IRHYTHM.

iRhythm Technologies, Inc.

IRTC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

iRhythm Technologies, Inc.

IRTC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IRTC